Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT
Clemens Mingels(University of Bern), Lorenzo Nardo(University of California, San Francisco), Hande Nalbant(University of California, Davis), Ramsey D. Badawi(University of California, Davis), Michele Guindani(University of California, Los Angeles), Axel Rominger(University Hospital of Bern), Yasser G. Abdelhafez(University of California, Davis), Mohammad H. Madani(University of California, Davis), Jonathan W. Riess(University of California Davis Medical Center), Fatma Şen(University of California, Davis), Benjamin A. Spencer(University of California, Davis), Ahmadreza Ghasemiesfe(University of California, Davis)
Cited by 12
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care
|Journal of Nuclear Medicine|2017|741